Research programme: antimalarial implants - Titan Pharmaceuticals

Drug Profile

Research programme: antimalarial implants - Titan Pharmaceuticals

Alternative Names: Atovaquone implant; Doxycycline implant; Piperaquine implant; ProNeura™ antimalarial implants; ProNeura™ antimalarial implants - Titan; ProNeura™ atovaquone implant; ProNeura™ doxycycline implant; ProNeura™ piperaquine implant

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Antimalarials; Piperazines; Quinolines; Small molecules; Tetracyclines
  • Mechanism of Action Electron transport complex I inhibitors; Hemozoin inhibitors; Protein 30S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 06 Jul 2017 Titan Pharmaceuticals establishes CRADA with the Walter Reed Army Institute of Research and Southwest Research Institute for the development of ProNeura™ based implants in Malaria
  • 06 Jul 2017 Preclinical trials in Malaria in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top